Should I Buy CRBP? CRBP 2026 Analysis

Should You Buy Corbus Pharmaceuticals Holdings Inc (CRBP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

8.630

1 Day change

-0.80%

52 Week Range

20.560

Analysis Updated At

2026/01/29

Corbus Pharmaceuticals Holdings Inc (CRBP) is not a strong buy for a beginner, long-term investor at this time. Despite positive analyst sentiment and undervaluation claims, the lack of immediate catalysts, insider selling, and weak technical indicators suggest holding off on buying until more clarity emerges on its growth potential and market sentiment.

Technical Analysis

The MACD is slightly positive but contracting, suggesting weakening momentum. RSI is neutral at 46.205, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 8.737, with key support at 8.095 and resistance at 9.378. Overall, the technical indicators do not suggest a strong entry point.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analysts highlight the company's undervaluation and potential large sales opportunities in oncology and obesity. RBC Capital maintains an Outperform rating with a price target of $53, indicating significant upside potential.

Neutral/Negative Catalysts

Insiders are selling heavily, with a 2235.89% increase in selling over the last month. The stock has a high probability of short-term declines (-17.04% in the next week, -18.19% in the next month). No recent news or congress trading data to support positive sentiment.

Financial Performance

In Q3 2025, revenue remained at $0, with no growth YoY. Net income improved by 69.35% YoY but remains negative at -$23.34M. EPS also improved by 65.22% YoY but is still negative at -1.9. Gross margin remains at 0%. Overall, financials show improvement in losses but no revenue generation, which is concerning for long-term growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are optimistic, with RBC Capital maintaining an Outperform rating and a $53 price target, citing undervaluation and potential in oncology and obesity. However, the firm also lowered its price target from $55 to $53, reflecting some caution.

8 Analyst Rating

Wall Street analysts forecast CRBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBP is 46.71 USD with a low forecast of 38 USD and a high forecast of 53 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 8.700

Low

Averages

46.71

High

Current: 8.700

Low

Averages

46.71

High

RBC Capital

Outperform

maintain

$53

AI Analysis

2025-12-11

Reason

RBC Capital

Price Target

$53

AI Analysis

2025-12-11

maintain

Outperform

Reason

RBC Capital notes that Corbus Pharmaceuticals has disclosed updates from its Phase I SAD/MAD study of CRB-913, a CB1 receptor inverse agonist, and management also hosted a conference call to discuss the data in detail. Early hints at efficacy and possibility Corbus could navigate a therapeutic window better than prior CB1 efforts should draw attention to this under-the-radar asset, with more robust de-risking data potentially only a few quarters away. At a $35M EV, with a cancer drug in '701 RBC views as low-risk, and a higher-risk but potentially very large-opportunity obesity asset, the firm believes the company is undervalued. The firm has an Outperform rating on the shares with a price target of $53.

Stifel

Stephen Willey

Buy

maintain

$28 -> $32

2025-12-04

Reason

Stifel

Stephen Willey

Price Target

$28 -> $32

2025-12-04

maintain

Buy

Reason

Stifel analyst Stephen Willey raised the firm's price target on Crescent Biopharma to $32 from $28 and keeps a Buy rating on the shares. The firm believes the Kelun deal creates "greater pipeline and CR-001 development and optionality," with Crescent "securing ex-Greater China rights to an ADC with a clinically-validated target antigen and linker/payload and positioning itself to leverage data generated from Kelun's interrogation of CR-001-based combinations with its other ADCs."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRBP

Unlock Now

CRBP Should I Buy

CRBP Should I Buy

Should You Buy Corbus Pharmaceuticals Holdings Inc (CRBP) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch